Aidea Pharma-Tech

Aidea Pharma is a China-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for infectious diseases, particularly HIV/AIDS. The company's lead product, Ainuovirine (ACC007), is a third-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that has received marketing approval in China. Additionally, Aidea has launched Ainuomiti (ACC008), the first domestic triple-combination single-tablet regimen for HIV treatment in China. The company also maintains a research pipeline in the fields of inflammation and cardiovascular health. Aidea Pharma is listed on the Shanghai Stock Exchange's STAR Market and operates integrated R&D and manufacturing facilities. The company aims to address unmet medical needs in the Chinese market by providing high-quality, affordable alternatives to imported antiretroviral therapies.